The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Adelman Daniel C Md since 2017.
The trader's CIK number is 1222037.
At the time of the last reporting, Adelman Daniel C Md was the Chief Medical Officer of Aimmune Therapeutics, Inc.. (stock ticker symbol AIMT).
Also see all insider trading activities at Aimmune Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2020 | AIMT | 0 | $0 | 20,000 | $700,040 | 54,932 | $792,571 |
| 2019 | AIMT | 0 | $0 | 20,000 | $600,720 | 20,000 | $229,000 |
| 2018 | AIMT | 0 | $0 | 36,717 | $1,468,680 | 36,717 | $420,408 |
| 2017 | AIMT | 0 | $0 | 23,283 | $724,580 | 23,283 | $266,590 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2020-10-02 | AIMT | Option Ex | 34,932 | 11.45 | 399,971 |
| 2020-01-02 | AIMT | Sale | 20,000 | 35.00 | 700,040 |
| 2020-01-02 | AIMT | Option Ex | 20,000 | 19.63 | 392,600 |
| 2019-12-09 | AIMT | Sale | 20,000 | 30.04 | 600,720 |
| 2019-12-09 | AIMT | Option Ex | 20,000 | 11.45 | 229,000 |
| 2018-01-16 | AIMT | Sale | 9,933 | 40.00 | 397,320 |
| 2018-01-12 | AIMT | Option Ex | 26,784 | 11.45 | 306,676 |
| 2018-01-12 | AIMT | Sale | 26,784 | 40.00 | 1,071,360 |
| 2018-01-16 | AIMT | Option Ex | 9,933 | 11.45 | 113,732 |
| 2017-12-27 | AIMT | Sale | 3,283 | 40.00 | 131,320 |
| 2017-12-27 | AIMT | Option Ex | 3,283 | 11.45 | 37,590 |
| 2017-10-23 | AIMT | Sale | 10,000 | 34.33 | 343,260 |
| 2017-10-23 | AIMT | Option Ex | 10,000 | 11.45 | 114,500 |
| 2017-09-25 | AIMT | Option Ex | 10,000 | 11.45 | 114,500 |
| 2017-09-25 | AIMT | Sale | 10,000 | 25.00 | 250,000 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Adelman Daniel C Md (Chief Medical Officer of Aimmune Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.